Regulatory Approval (ANDA)
Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid
NSE
lupin
BSE
500257
Lupin Limited has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral Liquid. The product targets urea cycle disorders and addresses a market with annual sales of approximately USD 337 million.
PRICE-SENSITIVE TRIGGER
Event: US FDA Approval for ANDA Product
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: Enhances Lupin’s US portfolio and opens up revenue opportunities in a niche therapeutic segment
Key Metrics:
- Market Size: USD 337 million (IQVIA MAT Dec 2025)
Highlight:
- Entry into a ~$337 million US market with FDA-approved product
What Happened ?
Lupin Limited announced that it has received approval from the US Food and Drug Administration (US FDA) for its ANDA for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL). The product is a generic equivalent to Ravicti® Oral Liquid.
key highlights
Product & Market Details:
- Product: Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL)
- Approved under ANDA pathway
- Bioequivalent to reference drug Ravicti®
- Used for chronic management of urea cycle disorders (UCDs)
- Targets patients not manageable through diet or supplements alone
- Reference drug owned by Horizon Therapeutics (Amgen subsidiary)
- Applicable in the US pharmaceutical market
Note:
- The product addresses a niche but high-value therapeutic segment in the US market
Risk Analysis
Key Risks
- Competition from existing branded and generic players
- Pricing pressure in US generics market
- Regulatory compliance and supply chain execution
- Market adoption in a niche therapeutic segment
Worst Case Scenario
- If pricing pressure or competition intensifies, revenue potential may be lower than expected
Risk Level: Medium
Company Commentary
- US FDA approval received for ANDA product
- Product is bioequivalent to Ravicti®
- Targets urea cycle disorder treatment
- Market size estimated at USD 337 million
- Strengthens Lupin’s US generics portfolio
Official Exchange Filing: Lupin Limited